ASST three-lens brief
Evidence-based stock research on ASST. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
Price up 7.66% in the last session — a material single-day move. · Trading >3% below the 50-day MA — short-term weakness.
- Price up 7.66% in the last session — a material single-day move.
- Trading >3% below the 50-day MA — short-term weakness.
- Underperforming SPY by 20.7pp over 30 days.
- Analyst mean target $40.60 — 75% above current (5 analysts).
- Negative free cash flow last quarterly (-$103.27M).
ASST closed at $23.20 (+7.66%) as of 2026-11-12. Market cap: $2.95B. Price is below the 50-day MA and above the 200-day MA. Positives: price up 7.66% in the last session — a material single-day move.; analyst mean target $40.60 — 75% above current (5 analysts).. Concerns: trading >3% below the 50-day MA — short-term weakness.; underperforming SPY by 20.7pp over 30 days.. Last quarter: Revenue $2.70M, net income $474.80M, free cash flow -$103.27M.
Why three lenses on ASST, not one.
A single reasoning model has blind spots it doesn’t know about. We examine ASST across Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://www.clearpathinvest.app/embed/ASST" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath ASST brief"></iframe>